Skip to content
Screener

Alumis Inc. ALMS Business Segments — Nonoperating Income Expense

Similar metrics at other companies

Capricor Therapeutics logo
CAPRSingle Reportable — Nonoperating Income Expense
$2.83M+379%
LQD
LQDASingle Reportable — Nonoperating Income Expense
-$4.72M-60.5%
Merit Medical Systems logo
MMSISingle Reportable — Nonoperating Income Expense
$9.39M+405%
Pulse Biosciences, Inc. logo
PLSESingle Reportable — Nonoperating Income Expense
-$615K+44.4%
Aclaris Therapeutics logo
ACRSSingle Reportable — Nonoperating Income Expense
$2.73M-8.3%
Axcelis Technologies logo
ACLSSingle Reportable — Nonoperating Income Expense
$5.07M-16.0%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.54B+686%
Enterprise value$3.52B+940%
P/S421.8×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Total research and development expense81,54096,622
General and administrative expenses18,61022,295
Total operating expenses100,150118,917
Loss from operations(98,409)(101,528)
Total other income (expense), net5,3562,565
Net loss before income taxes(93,053)(98,963)
Income tax benefit
Net loss$(93,053)$(98,963)

Item 1. Financial Statements (Unaudited)

FAQ

What is Alumis Inc.'s business segments — nonoperating income expense?
Alumis Inc. (ALMS) reported business segments — nonoperating income expense of $5.36M in Q1 2026.
How has Alumis Inc.'s business segments — nonoperating income expense changed year-over-year?
Alumis Inc.'s business segments — nonoperating income expense increased by 108.8% year-over-year, from $2.57M to $5.36M.
What is the long-term trend for Alumis Inc.'s business segments — nonoperating income expense?
Over 2 years (2023 to 2025), Alumis Inc.'s business segments — nonoperating income expense has grown at a 696.7% compound annual growth rate (CAGR), from $3.18M to $201.92M.
What does business segments — nonoperating income expense mean?
This metric represents financial gains or losses generated from activities outside of the company's core biopharmaceutical operations, such as interest income, investment returns, or foreign exchange fluctuations. It provides insight into the company's treasury management and the impact of non-core financial activities on the overall bottom line. Monitoring this helps investors distinguish between operational performance and peripheral financial results.

Ask your AI about Alumis Inc.'s business segments — nonoperating income expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude